The road to finding a solution to the coronavirus looks even brighter now than ever as vaccine that is developed by AstraZeneca Plc and Oxford University gave a strong immune response in older adults, according to researchers, saying it may protect some of those deemed most vulnerable to the disease.
The results of the mid-stage trials which was published in The Lancet medical journal on Thursday, suggested that people above 70-years-old who carry a higher risk of succumbing to the virus could build robust immunity to the COVID-19.
The Oxford-AstraZeneca vaccine candidate is among the front-runners in the world pursuit for achieving a vaccine for the coronavirus.
Maheshi Ramasamy, a consultant and a co-lead investigator at the Oxford Vaccine Group, said, “The robust antibody and T-cell responses seen in older people in our study are encouraging.
“The populations at greatest risk of serious COVID-19 disease include people with existing health conditions and older adults.
“We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure.”
Currently, the researching team is conducting late-stage trials in order to confirm the findings.
The Phase III experiments is aimed at determining whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people or not, including people with underlying health conditions.
Good news is, the Lancet report assures the first efficacy report from these trials is possible in the coming weeks.